SG Americas Securities LLC raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 228.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 162,068 shares of the company's stock after purchasing an additional 112,725 shares during the quarter. SG Americas Securities LLC's holdings in Recursion Pharmaceuticals were worth $857,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in RXRX. Private Trust Co. NA purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $27,000. GAMMA Investing LLC raised its stake in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after acquiring an additional 2,026 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after acquiring an additional 1,353 shares during the period. NewEdge Advisors LLC raised its stake in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after acquiring an additional 2,387 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter valued at $54,000. Institutional investors and hedge funds own 89.06% of the company's stock.
Recursion Pharmaceuticals Stock Down 4.0%
Shares of RXRX traded down $0.20 during midday trading on Monday, hitting $4.83. The company had a trading volume of 21,213,277 shares, compared to its average volume of 15,444,669. The company's 50 day moving average price is $4.91 and its 200 day moving average price is $6.23. The stock has a market cap of $1.96 billion, a price-to-earnings ratio of -2.73 and a beta of 0.84. Recursion Pharmaceuticals, Inc. has a 52 week low of $3.79 and a 52 week high of $12.36. The company has a quick ratio of 4.11, a current ratio of 4.11 and a debt-to-equity ratio of 0.02.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business had revenue of $14.75 million during the quarter, compared to analyst estimates of $18.12 million. During the same period last year, the firm posted ($0.39) earnings per share. The company's quarterly revenue was up 7.2% on a year-over-year basis. On average, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Analyst Upgrades and Downgrades
A number of brokerages have recently commented on RXRX. Cowen reissued a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Morgan Stanley dropped their price target on shares of Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a research note on Monday, June 16th. Needham & Company LLC dropped their price target on shares of Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating on the stock in a research note on Tuesday, May 6th. Finally, Leerink Partners dropped their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating on the stock in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $7.00.
View Our Latest Research Report on RXRX
About Recursion Pharmaceuticals
(
Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
